Core Viewpoint - The release of the 2025 ACC/AHA hypertension clinical guidelines indicates a new direction for hypertension prevention and treatment, highlighting the need for innovative solutions like renal denervation (RDN) to address the global challenge of uncontrolled hypertension [1]. Group 1: Differences Between US and China Guidelines - The US guidelines emphasize early intervention and precise stratification, setting the hypertension threshold at 130/80 mmHg to promote proactive management [2]. - The control targets in the US guidelines recommend a universal goal of <130/80 mmHg, with further specifications for high cardiovascular risk patients to lower systolic pressure to <130 mmHg, ideally <120 mmHg [3]. - In contrast, the Chinese guidelines set the hypertension threshold at 140/90 mmHg, aligning with local epidemiological characteristics and focusing on practical clinical management [4][5]. Group 2: RDN Clinical Application Under Guidelines - The 2025 US hypertension guidelines outline a comprehensive process for RDN application, emphasizing "precise selection, collaborative decision-making, and long-term management" [6]. - RDN is primarily indicated for patients with resistant hypertension, specifically those requiring three or more antihypertensive medications without achieving control [7]. - A multidisciplinary team (MDT) is essential for evaluating patients for RDN, ensuring thorough screening for secondary hypertension and contraindications [9]. Group 3: RDN as a New Treatment Option - RDN is recognized as a valuable adjunct treatment for resistant hypertension, with a recommendation level of 2b, B-R in the 2025 guidelines, indicating its use under specific conditions [11]. - The Iberis RDN system demonstrates significant efficacy, with a study showing a 13 mmHg reduction in 24-hour ambulatory systolic blood pressure and a 21 mmHg reduction in office systolic blood pressure at six months post-treatment [13]. - RDN offers a continuous blood pressure-lowering effect, providing a promising solution for patients with difficult-to-treat hypertension [13][14].